The origin and phenotype of stem cells in human prostate cancer remains a subject of much conjecture. In this scenario, CD133 has been successfully used as a stem cell marker in both normal prostate and prostate cancer. However, cancer stem cells have been identified without the use of this marker, opening up the possibility of a CD133 negative cancer stem cell. In this chapter, we review the current literature regarding prostate cancer stem cells, with specific reference to the expression of CD133 as a stem cell marker to identify and purify stem cells in normal prostate epithelium and prostate cancer. © 2013 Springer Science+Business Media New York.
CITATION STYLE
Pellacani, D., Oldridge, E. E., Collins, A. T., & Maitland, N. J. (2013). Prominin-1 (CD133) expression in the prostate and prostate cancer: A marker for quiescent stem cells. Advances in Experimental Medicine and Biology, 777, 167–184. https://doi.org/10.1007/978-1-4614-5894-4_11
Mendeley helps you to discover research relevant for your work.